Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

May 31, 2013

Conditions
Multiple MyelomaNon-Hodgkins LymphomaHodgkins Disease
Interventions
DRUG

G-CSF plus Plerixafor

"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."

Trial Locations (1)

27705

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Duke University

OTHER

NCT00901225 - Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant | Biotech Hunter | Biotech Hunter